| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Syrosingopine |
Is a |
True |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Reserpine - chemical |
Is a |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Rescinnamine |
Is a |
True |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Alpha-2 adrenergic receptor agonist |
Is a |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing alpha-2 adrenergic receptor agonist (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing deserpidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Dexmedetomidine hydrochloride 100mcg/mL injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Deserpidine 250 microgram and methyclothiazide 5 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely deserpidine 500 microgram and methyclothiazide 5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Centrally acting hypotensive agent |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing reserpine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Reserpine 100% |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Chlorothiazide 250 mg and reserpine 125 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely chlorothiazide 500 milligram and reserpine 125 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydralazine hydrochloride 25 mg and hydrochlorothiazide 15 mg and reserpine 100 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 25 mg and reserpine 125 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 50 mg and reserpine 125 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyclothiazide 2.5 mg and reserpine 100 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing chlorothiazide and reserpine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing hydrochlorothiazide and reserpine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing deserpidine and methyclothiazide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing hydralazine hydrochloride and hydrochlorothiazide and reserpine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing methyclothiazide and reserpine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely guanfacine hydrochloride 1 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Chlorothiazide 250 mg and methyldopa 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine-containing product in transdermal dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanfacine hydrochloride 1mg extended release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Apraclonidine 1% intra-ocular solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 100microgram extended release film |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine hydrochloride 100mcg/mL injection solution 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing clonidine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Lofexidine hydrochloride 200 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing chlortalidone and clonidine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing dexmedetomidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyldopa 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine hydrochloride 100 microgram/mL prolonged-release oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanfacine hydrochloride 4mg extended release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 7.5mg/unt |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 2.5mg/unt |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing guanabenz (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 25 mg and methyldopa 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 200microgram extended release film |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| chlorhydrate de clonidine 150 microgrammes/mL, ampoule de 1 mL de solution pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely guanfacine hydrochloride 2 milligram/1 each conventional release oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Apraclonidine (as apraclonidine hydrochloride) 5 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 50 mg and methyldopa 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing apraclonidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyldopa 250 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing guanfacine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 30 mg and methyldopa 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanfacine hydrochloride 3mg extended release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Hydrochlorothiazide 15 mg and methyldopa 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 5mg patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 0.1mg patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Chlortalidone 15 mg and clonidine hydrochloride 200 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine hydrochloride 0.5mg/mL injection solution 10mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine hydrochloride 100 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanabenz acetate 8 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanfacine hydrochloride 2mg extended release tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing clonidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely clonidine hydrochloride 300 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyldopa 125 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely chlortalidone 15 milligram and clonidine hydrochloride 300 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Guanabenz acetate 4 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing guanfacine hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Methyldopa 250 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing hydrochlorothiazide and methyldopa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing methyldopa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 300microgram extended release film |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing lofexidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine 4mg/patch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing chlorothiazide and methyldopa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine hydrochloride 250micrograms m/r capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Clonidine hydrochloride 200 microgram oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing precisely clonidine hydrochloride 25 microgram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing methyldopa in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
| Product containing central alpha-adrenoceptor agonist |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Centrally acting hypotensive agent (substance) |
Inferred relationship |
Some |
|
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]